Evidence map›Paper›PMID 31259037›Full record

ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2019

Comparing the Study Populations in Dietary Supplement and Drug Clinical Trials for Metabolic Syndrome and Related Disorders.

Zhe He, Rubina F Rizvi, Fan Yang, Terrence J Adam, Rui Zhang

Open access · greenAbstract read
In one paragraph

Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review of Clinical Research Informatics.Yearbook of medical informatics · 2020
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Zhe HeSchool of Information, Florida State University, Tallahassee, FL, USA.
Rubina F RizviInstitute for Health Informatics and.
Fan YangSchool of Health Policy & Management, Nanjing Medical University, Nanjing, China.
Terrence J AdamInstitute for Health Informatics and.
Rui ZhangInstitute for Health Informatics and.
University of Minnesota · USFlorida State University · USNanjing Medical University · CN

Funding

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Institutional Career Development CoreKL2TR002492 · NCATS · UNIVERSITY OF MINNESOTA · PI INGBAR, DAVID H · 2018 to 2022
$6.3M
Bridging the Semantic Gap Between Research Eligibility Criteria and Clinical DataR01LM009886 · NLM · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WENG, CHUNHUA · 2009 to 2020
$5.3M
A Translational Informatics Framework to Mine Efficacy and Safety of Dietary SupplementsR01AT009457 · NCCIH · UNIVERSITY OF MINNESOTA · PI RUI ZHANG · 2017 to 2026
$4.1M
Systematic Analysis of Clinical Study Generalizability Assessment Methods with InformaticsR21AG061431 · NIA · FLORIDA STATE UNIVERSITY · PI BIAN, JIANG, HE, ZHE · 2019 to 2020
$793k
NCATS NIH HHS KL2 TR002492NCATS NIH HHS UL1 TR002494NCCIH NIH HHS R01 AT009457NIA NIH HHS R21 AG061431NLM NIH HHS R01 LM009886
6 · The paper itself

Abstract

Clinical trials are essential in exploring the safety and efficacy of a new intervention. However, restrictive eligibility criteria pose recruitment challenges that could prolong study durations and reduce study generalizability to the real-world population. The objective of this study is to compare the study populations of dietary supplement (DS) and drug trials on metabolic syndrome related conditions. Using the COMPACT database, we retrieved the DS and drug trials related to metabolic syndrome and performed aggregate analyses on the study populations with respect to various quantitative eligibility criteria. We also extracted and compared baseline characteristics, both quantitative and qualitative, of recruited patients in completed trials. We found similarities and differences in baseline characteristics of enrolled patients between drug and DS clinical trials on metabolic syndrome-related conditions. This comparative aggregate analysis is an initial step towards improving patient recruitment efficacy and population representativeness for clinical trials across conditions and intervention types.

Identifiers

PMID31259037
PMCPMC6568097
OpenAlexW2997372541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.